Summary
34.37 0.28(0.82%)07/05/2024
Dyne Therapeutics Inc (DYN)
Dyne Therapeutics Inc (DYN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.82 | -2.85 | 4.50 | 29.97 | 91.37 | 210.48 | 0.00 | 43.81 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 34.37 | |
| Open | 33.86 | |
| High | 34.44 | |
| Low | 33.59 | |
| Volume | 405,959 | |
| Change | 0.28 | |
| Change % | 0.82 | |
| Avg Volume (20 Days) | 670,781 | |
| Volume/Avg Volume (20 Days) Ratio | 0.61 | |
| 52 Week Range | 6.40 - 36.60 | |
| Price vs 52 Week High | -6.09% | |
| Price vs 52 Week Low | 437.03% | |
| Range | 1.51 | |
| Gap Up/Down | -1.27 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,367 | |
| EBIDTA | 753,000,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.1900 | |
| WallStreet Target Price | 34.75 | |
| Book Value | 8.1120 | |
| Earnings Per Share | -2.5570 | |
| EPS Estimate Current Quarter | -0.6400 | |
| EPS Estimate Next Quarter | -0.7000 | |
| EPS Estimate Current Year | -2.9100 | |
| EPS Estimate Next Year | -3.7600 | |
| Diluted EPS (TTM) | -2.5570 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.1866 | |
| Return on equity (TTM) | -0.3231 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6325 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 51,528,500 | |
| Shares Float | 19,406,210 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 3.20 | |
| Institutions (%) | 98.41 | |
06/24 07:30 EST - globenewswire.com
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 23-26 in Fort Lauderdale, FL.
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 23-26 in Fort Lauderdale, FL.
06/13 16:40 EST - globenewswire.com
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models -
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models -
05/30 07:30 EST - globenewswire.com
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.
05/28 07:30 EST - globenewswire.com
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $374.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $374.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.
05/22 08:00 EST - forbes.com
Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?
Dyne Therapeutics stock (NASDAQ NASDAQ : DYN), a biotechnology company focused on advancing genetically driven muscle diseases therapeutics, saw a significant 28% rise on Monday, May 20. This move came in after the company released a positive clinical trial data for its experimental drugs – DYNE-101 – for patients with myotonic dystrophy type 1, and DYNE-251 – for patients with Duchenne muscular dystrophy.
Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?
Dyne Therapeutics stock (NASDAQ NASDAQ : DYN), a biotechnology company focused on advancing genetically driven muscle diseases therapeutics, saw a significant 28% rise on Monday, May 20. This move came in after the company released a positive clinical trial data for its experimental drugs – DYNE-101 – for patients with myotonic dystrophy type 1, and DYNE-251 – for patients with Duchenne muscular dystrophy.
05/21 20:39 EST - globenewswire.com
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $325.5 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about May 24, 2024, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $325.5 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about May 24, 2024, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
05/21 13:30 EST - zacks.com
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
05/20 16:01 EST - globenewswire.com
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.
05/20 15:53 EST - https://www.benzinga.com
Why Is Dyne Therapeutics Stock Soaring On Monday?
Monday, Earlier this year, released initial clinical data from both trials. In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splicing correction. DYNE-101 demonstrated an improvement in myotonia as measured by video hand opening time (vHOT) in all reported cohorts. The 1.8 mg/kg Q4W group had a mean 3.1-second benefit in myotonia at 3 months, increasing to 4.4 seconds at 12 months. In addition, the 5.4 mg/kg Q8W cohort had a mean 4.5-second improvement in myotonia at 3 months. DYNE-101 demonstrated an improvement in muscle strength and early and sustained potential benefit in the 10-meter Walk/Run Test and 5-times to Stand Test. Dyne reported efficacy data from 8 male patients with DMD amenable to exon 51 skipping enrolled in the 10 mg/kg (approximate PMO dose) cohort of the randomized, placebo-controlled MAD portion of the DYNE-251 DELIVER trial. 10 mg/kg of DYNE-251 Q4W demonstrated dose-dependent exon skipping and dystrophin expression. DYNE-251 reached levels of dystrophin expression that exceeded levels reported in a clinical trial for the current weekly standard of care for DMD exon 51, eteplirsen, at 6 months1 with a 12-fold lower PMO dose. DYNE-251 also demonstrated encouraging trends in multiple functional endpoints. Patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change (unadjusted for muscle content) from baseline at 6 months. Eteplirsen reached a mean absolute unadjusted dystrophin level of 0.30% of normal and a 0.06% change from baseline at 6 months. When adjusting for muscle content, the DYNE-251 treated group reached 7.64% mean absolute dystrophin, greater than levels reported by peptide conjugate PMOs in clinical development. Trends in improvement were observed in multiple functional endpoints in the 10 mg/kg DYNE-251 Q4W group at 6 months. DYN shares are up 27.80% at $35.36 at the last check Monday.
Why Is Dyne Therapeutics Stock Soaring On Monday?
Monday, Earlier this year, released initial clinical data from both trials. In the ACHIEVE trial, patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splicing correction. DYNE-101 demonstrated an improvement in myotonia as measured by video hand opening time (vHOT) in all reported cohorts. The 1.8 mg/kg Q4W group had a mean 3.1-second benefit in myotonia at 3 months, increasing to 4.4 seconds at 12 months. In addition, the 5.4 mg/kg Q8W cohort had a mean 4.5-second improvement in myotonia at 3 months. DYNE-101 demonstrated an improvement in muscle strength and early and sustained potential benefit in the 10-meter Walk/Run Test and 5-times to Stand Test. Dyne reported efficacy data from 8 male patients with DMD amenable to exon 51 skipping enrolled in the 10 mg/kg (approximate PMO dose) cohort of the randomized, placebo-controlled MAD portion of the DYNE-251 DELIVER trial. 10 mg/kg of DYNE-251 Q4W demonstrated dose-dependent exon skipping and dystrophin expression. DYNE-251 reached levels of dystrophin expression that exceeded levels reported in a clinical trial for the current weekly standard of care for DMD exon 51, eteplirsen, at 6 months1 with a 12-fold lower PMO dose. DYNE-251 also demonstrated encouraging trends in multiple functional endpoints. Patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change (unadjusted for muscle content) from baseline at 6 months. Eteplirsen reached a mean absolute unadjusted dystrophin level of 0.30% of normal and a 0.06% change from baseline at 6 months. When adjusting for muscle content, the DYNE-251 treated group reached 7.64% mean absolute dystrophin, greater than levels reported by peptide conjugate PMOs in clinical development. Trends in improvement were observed in multiple functional endpoints in the 10 mg/kg DYNE-251 Q4W group at 6 months. DYN shares are up 27.80% at $35.36 at the last check Monday.
05/20 12:47 EST - investors.com
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.
05/20 11:48 EST - https://www.schaeffersresearch.com
Tech Surge Boosts Nasdaq to Record Highs
Tech Surge Boosts Nasdaq to Record Highs The S&P 500 is wavering below all-time highs as well Laura McCandless Deputy Editor May 20, 2024 at 11:48 AM SPX|IXIC|DJI All three major indexes are higher midday The Nasdaq Composite Index (IXIC) is up triple digits and marking new record highs, thanks to rising tech stocks. Nvidia (NVDA), specifically, is in focus as analysts throw in bull notes ahead of this week's earnings report. The Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) are enjoying more modest gains, though the latter is nearing its own all-time highs. Meanwhile, bond yields are also rising, amid comments from several Fed officials regarding inflation. Continue reading for more on today's market, including: Elliott built a $1 billion-plus stake in this electrical stock. Morgan Stanley upgrades Micron Technology stock. Plus, options traders target HIMS; DYN soars on trial data; and Li Auto's earnings disappoint. Options bulls are blasting Hims & Hers Health Inc (NYSE:HIMS), after the healthcare platform added GLP-1 injections to its weight-loss services, a compounded and cheap version of Novo Nordisk's (NVO) semaglutide (the active ingredient in Wegovy). So far, 100,000 calls have been exchanged -- 18 times the call volume typically seen at this point -- in comparison to 26,000 puts. The weekly 5/24 20-strike call is the most popular by far, where new positions are being opened. At last glance, HIMS was up 29.5% at $18.87, earlier hitting a three-year peak of $20.11. Dyne Therapeutics Inc (NASDAQ:DYN) is up 24.5% at $34.46 at last glance, after the biotech reported positive data for its muscular dystrophy treatments. In response, H.C. Wainwright raised its price target to $48 from $36, while Jefferies lifted its price objective to $42 from $36. Today's pop has DYN soaring to record highs, up 157.9% since the start of 2024. Meanwhile, the shares of Li Auto Inc (NASDAQ:LI) are trading at 52-week lows, down 14.1% at $21.37, after the China-based electric vehicle (EV) stock's disappointing first-quarter results. On the short sell restricted (SSR) list amid the volatility, LI is down roughly 43% year to date. Follow @Schaeffers (function () { var po = document.createElement('script'); po.type = 'text/javascript'; po.async = true; po.src = 'https://apis.google.com/js/platform.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(po, s); })();
Tech Surge Boosts Nasdaq to Record Highs
Tech Surge Boosts Nasdaq to Record Highs The S&P 500 is wavering below all-time highs as well Laura McCandless Deputy Editor May 20, 2024 at 11:48 AM SPX|IXIC|DJI All three major indexes are higher midday The Nasdaq Composite Index (IXIC) is up triple digits and marking new record highs, thanks to rising tech stocks. Nvidia (NVDA), specifically, is in focus as analysts throw in bull notes ahead of this week's earnings report. The Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) are enjoying more modest gains, though the latter is nearing its own all-time highs. Meanwhile, bond yields are also rising, amid comments from several Fed officials regarding inflation. Continue reading for more on today's market, including: Elliott built a $1 billion-plus stake in this electrical stock. Morgan Stanley upgrades Micron Technology stock. Plus, options traders target HIMS; DYN soars on trial data; and Li Auto's earnings disappoint. Options bulls are blasting Hims & Hers Health Inc (NYSE:HIMS), after the healthcare platform added GLP-1 injections to its weight-loss services, a compounded and cheap version of Novo Nordisk's (NVO) semaglutide (the active ingredient in Wegovy). So far, 100,000 calls have been exchanged -- 18 times the call volume typically seen at this point -- in comparison to 26,000 puts. The weekly 5/24 20-strike call is the most popular by far, where new positions are being opened. At last glance, HIMS was up 29.5% at $18.87, earlier hitting a three-year peak of $20.11. Dyne Therapeutics Inc (NASDAQ:DYN) is up 24.5% at $34.46 at last glance, after the biotech reported positive data for its muscular dystrophy treatments. In response, H.C. Wainwright raised its price target to $48 from $36, while Jefferies lifted its price objective to $42 from $36. Today's pop has DYN soaring to record highs, up 157.9% since the start of 2024. Meanwhile, the shares of Li Auto Inc (NASDAQ:LI) are trading at 52-week lows, down 14.1% at $21.37, after the China-based electric vehicle (EV) stock's disappointing first-quarter results. On the short sell restricted (SSR) list amid the volatility, LI is down roughly 43% year to date. Follow @Schaeffers (function () { var po = document.createElement('script'); po.type = 'text/javascript'; po.async = true; po.src = 'https://apis.google.com/js/platform.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(po, s); })();
05/20 06:30 EST - globenewswire.com
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -
05/19 08:00 EST - globenewswire.com
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.m. ET. This represents an update to Dyne's prior guidance for the second half of 2024. The company intends to issue a press release prior to the start of the event.
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.m. ET. This represents an update to Dyne's prior guidance for the second half of 2024. The company intends to issue a press release prior to the start of the event.
05/02 16:10 EST - globenewswire.com
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 -
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 -
03/27 16:05 EST - globenewswire.com
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox. The award was approved by the Compensation Committee of Dyne and was made as an inducement material to Mr. Cox's acceptance of employment with Dyne under Dyne's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox. The award was approved by the Compensation Committee of Dyne and was made as an inducement material to Mr. Cox's acceptance of employment with Dyne under Dyne's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
03/27 08:30 EST - globenewswire.com
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m. ET.
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m. ET.
03/25 07:30 EST - globenewswire.com
Dyne Therapeutics Announces CEO Transition
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -
Dyne Therapeutics Announces CEO Transition
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -
03/13 07:30 EST - globenewswire.com
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.
03/05 14:48 EST - seekingalpha.com
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033.
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033.
03/05 07:30 EST - globenewswire.com
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle -
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle -